Alector, Inc. - Common Stock (OQ:ALEC)

Feb 28, 2024 07:00 am ET
Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference (Boston,...
Feb 27, 2024 04:05 pm ET
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported fourth quarter and full year 2023 financial results and recent portfolio and business updates. As of December 31, 2023, Alector’s...
Feb 20, 2024 04:05 pm ET
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m. ET to discuss results for the fourth quarter...
Feb 08, 2024 07:00 am ET
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in PROGRESS-AD, the global Phase 2 clinical trial of AL101/GSK4527226 in patients with early Alzheimer’s disease (AD), including mild...
Feb 07, 2024 07:00 am ET
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to latozinemab, an investigational human monoclonal antibody designed to block...
Jan 19, 2024 09:20 am ET
Alector Announces Closing of Public Offering
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its underwritten public offering of shares of its common stock. Alector sold 10,869,566 shares of its common stock in...
Jan 17, 2024 08:54 am ET
Alector Announces Pricing of Public Offering of Common Stock
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million before...
Jan 16, 2024 04:01 pm ET
Alector Announces Proposed Public Offering of Common Stock
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public...
Dec 14, 2023 08:31 am ET
Thinking about buying stock in Cepton Inc, Amtech Systems, Super Micro Computer, Upstart Holdings, or Alector?
NEW YORK, Dec. 14, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CPTN, ASYS, SMCI, UPST, and ALEC.
Nov 28, 2023 07:00 am ET
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company’s TREM2 and progranulin (PGRN) programs. The events will...
Nov 08, 2023 07:00 am ET
Alector to Participate in the Stifel Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 11:30 a.m. ET. A...
Nov 07, 2023 04:05 pm ET
Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported third quarter 2023 financial results and recent portfolio and business updates. As of September 30, 2023, Alector’s cash, cash...
Oct 27, 2023 07:00 am ET
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GR
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has achieved target enrollment in INFRONT-3, the pivotal Phase 3 clinical trial of latozinemab (AL001). INFRONT-3 is...
Sep 07, 2023 07:00 am ET
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of...
Aug 31, 2023 07:00 am ET
Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare...
Aug 03, 2023 04:05 pm ET
Alector Reports Second Quarter 2023 Financial Results and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported second quarter 2023 financial results and recent portfolio and business updates. As of June 30, 2023, Alector’s cash, cash equivalents...
Jul 27, 2023 08:30 am ET
Alector to Host Mid-Year Earnings Conference Call
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Thursday, August 3, 2023, at 4:30 p.m. ET to discuss results for the second quarter...
Jun 06, 2023 07:00 am ET
Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13,...
May 04, 2023 04:05 pm ET
Alector Reports First Quarter 2023 Financial Results and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2023 financial results and recent portfolio and business updates. As of March 31, 2023, Alector’s cash, cash equivalents...
May 02, 2023 07:00 am ET
Alector to Participate in the BofA Securities 2023 Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a corporate presentation at the BofA Securities 2023 Healthcare Conference in Las Vegas on Wednesday,...
Mar 01, 2023 04:05 pm ET
Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: Cowen 43rd Annual Health Care Conference (Boston,...
Feb 28, 2023 04:05 pm ET
Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported fourth quarter and full year 2022 financial results and recent portfolio and business updates. As of December 31, 2022, Alector’s cash,...
Dec 08, 2022 04:30 pm ET
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on December 6, 2022, the compensation committee of Alector’s board of directors granted 8 (eight)  new...
Nov 29, 2022 11:05 am ET
Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, reported safety and biomarker data from a first-in-human Phase 1 healthy volunteer study of AL101, a human monoclonal...
Nov 08, 2022 04:05 pm ET
Alector Reports Third Quarter 2022 Financial Results and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today reported third quarter 2022 financial results and recent portfolio and business updates. As of September 30, 2022,...
Nov 07, 2022 07:00 am ET
Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that management will participate in the following upcoming investor conferences: Guggenheim 4th Annual...
Nov 03, 2022 04:30 pm ET
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on November 1, 2022, the compensation committee of Alector’s board of directors granted five  new...
Oct 13, 2022 08:00 am ET
Alector Announces Promotion of Clare Hunt to Chief People Officer
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced the promotion of Clare Hunt to Chief People Officer. In this newly created role, Ms. Hunt, who has led the...
Oct 06, 2022 04:30 pm ET
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on October 1, 2022, the compensation committee of Alector’s board of directors granted six new...
Sep 12, 2022 10:15 am ET
Moore Kuehn, PLLC Encourages Investors of Alector, Inc. to Contact Law Firm
Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ: ALEC) breached their fiduciary duties to shareholders. The investigation concerns potential...
Sep 12, 2022 07:00 am ET
Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer’s Disease (AD)
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced the initiation of the first-in-human Phase 1 trial of AL044. The study is investigating the safety profile,...
Sep 07, 2022 07:00 am ET
Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: H.C. Wainwright 24th Annual Global Investment...
Aug 04, 2022 04:05 pm ET
Alector Reports Second Quarter 2022 Financial Results and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported second quarter 2022 financial results and recent portfolio and business updates. As of June 30, 2022, Alector’s cash, cash equivalents...
Jun 08, 2022 07:00 am ET
Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15,...
May 27, 2022 04:30 pm ET
Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation committee of Alector’s board of directors granted Gary Romano, M.D., Ph.D., the company’s newly-hired Chief...
May 05, 2022 04:05 pm ET
Alector Reports First Quarter 2022 Financial Results and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2022 financial results and recent portfolio and business updates. As of March 31, 2022, Alector’s cash, cash...
May 04, 2022 07:00 am ET
Alector to Participate at the BofA Securities 2022 Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Thursday, May 12, 2022, at 11:20...
Apr 07, 2022 11:12 am ET
Moore Kuehn, PLLC Encourages Investors of ALEC, RETA, ASXM, and PTCT to Contact Law Firm
Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ: ALEC), Reata Pharmaceuticals, Inc. (NASDAQ: RETA), Axsome Therapeutics, Inc. (NASDAQ: AXSM), and PTC...
Mar 29, 2022 04:05 pm ET
Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company’s global...
Mar 15, 2022 08:00 am ET
Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented results from the INFRONT-2 Phase 2 clinical trial of AL001 (latozinemab) in frontotemporal dementia patients (FTD) with a C9orf72 genetic...
Mar 09, 2022 07:00 am ET
Alector to Present at Upcoming Healthcare Conferences
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will present at the following upcoming investor conferences: Barclays Global Healthcare Conference (Miami, Florida)...
Mar 08, 2022 07:00 am ET
Alector to Present New AL001 Data at AD/PD™ 2022
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced an oral presentation at the upcoming 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) being held March...
Mar 01, 2022 04:30 pm ET
Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation committee of Alector’s board of directors granted Marc Grasso, M.D., the company’s newly-hired Chief Financial...
Mar 01, 2022 04:05 pm ET
Alector to Participate at the Cowen 42nd Annual Health Care Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced management will participate in a panel discussion at the Cowen Annual Health Care...
Feb 24, 2022 04:05 pm ET
Alector Reports Fourth Quarter and Full Year 2021 Financial Results
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today reported fourth quarter and full year 2021 financial results and summarized recent portfolio and...
Feb 07, 2022 08:30 am ET
Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso...
Jan 03, 2022 04:30 pm ET
Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation committee of Alector’s board of directors granted Sara Kenkare-Mitra, Ph.D., the company’s newly-hired President...
Dec 15, 2021 08:30 am ET
Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development. In this newly created role, Dr....
Nov 12, 2021 01:50 pm ET
Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented encouraging results from the company’s INFRONT-2 Phase 2 clinical trial of AL001 at the 14th Clinical Trials on Alzheimer's Disease (CTAD)...
Nov 12, 2021 07:00 am ET
Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cancer’s 36th Annual Meeting
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented preclinical data from its AL009 immuno-oncology program in poster at the Society for Immunotherapy of Cancer’s 36th Annual Meeting....
Nov 10, 2021 08:30 am ET
Alector Presents New Data from Multiple Pipeline Programs at 2021 CTAD Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, shared data from its AL003 and AL101 programs in poster presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference being held...
Nov 08, 2021 04:05 pm ET
Alector to Present at the Stifel 2021 Virtual Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector, will participate in a fireside chat at the Stifel 2021 Virtual...
Nov 04, 2021 04:05 pm ET
Alector Reports Third Quarter 2021 Financial Results
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported third quarter 2021 financial results and summarized recent portfolio and business updates. As of September 30, 2021, Alector’s cash,...
Nov 03, 2021 04:50 pm ET
Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference being held November 9-12, 2021 virtually and in...
Sep 28, 2021 08:30 am ET
Alector Announces Appointment of Elizabeth A. Garofalo, M.D., to its Board of Directors
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabeth (Betsy) A. Garofalo, M.D., to the Company’s Board of Directors. Dr. Garofalo is a veteran biopharmaceutical...
Sep 09, 2021 08:30 am ET
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in a Phase 2 clinical study evaluating the safety, tolerability, pharmacokinetics and...
Sep 07, 2021 04:30 pm ET
Alector Provides Executive Leadership Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., and Robert Paul, M.D., Ph.D., will be stepping down from their respective roles as...
Sep 02, 2021 07:00 am ET
Alector to Present at Upcoming Virtual Healthcare Conferences
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming virtual investor conferences: Citi’s 16th Annual Biopharma Virtual...
Aug 03, 2021 05:09 pm ET
Alector Reports Second Quarter 2021 Financial Results
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported financial results for the second quarter 2021. As of June 30, 2021, Alector’s cash, cash equivalents and investments totaled $319.6...
Jul 29, 2021 10:10 am ET
Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented promising results from the company’s INFRONT-2 Phase 2 clinical trial of AL001 at the Alzheimer’s Association International Conference (AAIC...
Jul 21, 2021 04:35 pm ET
Alector to Present New Data from Frontotemporal Dementia and Alzheimer’s Disease Programs at the 2021 Alzheimer’s Association International Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the upcoming 2021 Alzheimer’s Association International Conference being held July 26-30, 2021 virtually and in...
Jul 02, 2021 09:31 am ET
Thinking about trading options or stock in Alector, Alibaba, Sony, Exxon Mobil, or Nio?
NEW YORK, July 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALEC, BABA, SONY, XOM, and NIO.
Jul 02, 2021 07:38 am ET
Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
Alector, Inc. (Nasdaq: ALEC) and GlaxoSmithKline plc (LSE/NYSE: GSK), today announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101)...
Jun 03, 2021 04:05 pm ET
Alector to Present at Upcoming Virtual Healthcare Conferences
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in fireside chats at the...
Jun 02, 2021 06:31 am ET
CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced a new observational study to understand the prevalence of genetic mutations in...
May 26, 2021 04:05 pm ET
Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it will host a virtual key opinion leader event focused on frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)...
May 06, 2021 04:05 pm ET
Alector to Present at the BofA Securities 2021 Virtual Health Care Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at...
May 05, 2021 04:05 pm ET
Alector Reports 2021 First Quarter Financial Results and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced business updates and financial results for the first quarter ended March 31, 2021. “Positive momentum continues to build throughout...
Mar 25, 2021 04:05 pm ET
Alector to Present at Stifel’s 3rd Annual CNS Day
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at...
Mar 04, 2021 04:05 pm ET
Alector to Present at the Barclays Global Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at...
Feb 25, 2021 04:05 pm ET
Alector Reports 2020 Fourth Quarter and Full Year Financial Results and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced business updates and financial results for the fourth quarter ended December 31, 2020. “In 2020, we made significant progress across...
Jan 25, 2021 08:30 am ET
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in INVOKE-2, a Phase 2 clinical study evaluating the efficacy and safety of AL002 in slowing...
Jan 20, 2021 04:15 pm ET
Alector Announces Departure of Chief Business Officer
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that chief business officer (CBO), Sabah Oney, Ph.D., will be leaving the Company to pursue other opportunities. Shehnaaz Suliman,...
Jan 07, 2021 04:05 pm ET
Alector Provides 2021 Corporate Portfolio Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today provided a preview of its planned clinical and research priorities for 2021. “In 2020, we advanced AL001 into a pivotal Phase 3 clinical trial...
Nov 11, 2020 04:05 pm ET
Alector to Present at the Stifel 2020 Virtual Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer of Alector, will participate in a fireside chat at the Stifel 2020 Virtual Healthcare...
Nov 10, 2020 04:05 pm ET
Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and financial results for the third quarter ended September 30, 2020. “We continued to make progress across our...
Nov 02, 2020 07:43 am ET
Alector Provides Update on Arbitration Proceedings with Dr. Asa Abeliovich
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that an independent arbitrator issued an interim, confidential decision in favor of the company in its dispute with Asa Abeliovich,...
Oct 22, 2020 04:05 pm ET
Alector to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forums
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of the Company’s immuno-oncology team will provide an overview of the company’s early-stage immuno-oncology research,...
Sep 03, 2020 04:05 pm ET
Alector to Participate at Virtual Investor Conferences in September
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of management will participate in fireside chats at the following upcoming virtual investor conferences: Citi’s 15th...
Aug 11, 2020 04:05 pm ET
Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and financial results for the second quarter ended June 30, 2020. “I am proud of the continued progress across our...
Aug 04, 2020 08:30 am ET
Alector to Present at the BTIG Virtual Biotechnology Conference 2020
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020...
Jul 28, 2020 06:00 pm ET
Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced preliminary data from its Phase 1b and open-label Phase 2 studies of AL001, for the treatment of people with frontotemporal dementia...
Jul 24, 2020 08:30 am ET
Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced dosing of the first patient in its pivotal Phase 3 clinical trial, named INFRONT-3, evaluating AL001 in people at risk for or with...
Jul 21, 2020 05:00 pm ET
Alector to Present Data from the AL001 Phase 2 Open-Label Study in Frontotemporal Dementia at the 2020 Alzheimer’s Association International Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the company will highlight preliminary data from a Phase 2 open-label study evaluating AL001 in individuals with frontotemporal...
Jun 25, 2020 09:00 am ET
Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medici
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, announced the publication of preclinical and preliminary Phase 1 clinical data of AL002, a TREM2 activating antibody, in The Journal of Experimental...
Jun 03, 2020 04:01 pm ET
Alector to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of management will participate in a virtual fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference...
May 13, 2020 08:00 am ET
Alector Reports 2020 First Quarter Financial Results and Business Highlights
Alector, Inc. (Nasdaq: ALEC), a clinical- stage biotechnology company pioneering immuno-neurology, today announced business highlights and financial results for the first quarter ended March 31, 2020. “At Alector we are committed to...
May 07, 2020 08:30 am ET
Alector to Present at the Bank of America Securities Virtual Health Care Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will present at the Bank of America...
Mar 25, 2020 05:00 pm ET
Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company and leader in the discovery and development of therapeutics that harness the innate immune system, and Innovent Biologics, a leading Chinese biopharmaceutical company that...
Mar 24, 2020 04:05 pm ET
Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business Highlights
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced company highlights and financial results for the fourth quarter and year ended December 31, 2019. “At Alector, we envision a world...
Mar 23, 2020 08:30 am ET
Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors
Alector, Inc. (Nasdaq: ALEC) today announced the addition of Paula Hammond, Ph.D., to the Company’s Board of Directors. Dr. Hammond is the David H. Koch Chair Professor of Engineering and Department Head, Chemical Engineering at the Massachusetts...
Feb 24, 2020 08:30 am ET
Alector to Present at the Cowen 40th Annual Health Care Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector, will present at the Cowen 40th Annual Health Care...
Feb 05, 2020 08:00 am ET
Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AL101 for the treatment of patients with...
Feb 03, 2020 06:00 pm ET
Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its previously announced underwritten public offering of 9,602,500 shares of its common stock at the public offering...
Jan 31, 2020 08:00 am ET
Alector Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the underwriters fully exercised their option to purchase an additional 1,252,500 shares of common stock at the offering price of...
Jan 29, 2020 09:42 pm ET
Alector Announces Upsizing and Pricing of Public Offering
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an upsized underwritten public offering of 8,350,000 shares of its common stock at a price of $25.00 per share pursuant...
Jan 28, 2020 08:30 am ET
Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer’s Disease Patients
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INTERCEPT clinical study of AL003. AL003 is...
Jan 27, 2020 04:05 pm ET
Alector Announces Proposed Public Offering of Common Stock
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it intends to offer and sell, subject to market and other conditions, 5,095,000 shares of its common stock in an underwritten public...
Jan 08, 2020 08:30 am ET
Alector to Present at the J.P. Morgan 38th Annual Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector, will present a company overview at the J.P. Morgan...
Jan 06, 2020 08:30 am ET
Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that in December 2019, it initiated dosing in healthy volunteers in its Phase 1 study of AL101, an investigational product candidate...
Dec 20, 2019 08:30 am ET
Alector Added to the NASDAQ Biotechnology Index
Alector Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective prior to market...
Dec 13, 2019 06:30 am ET
Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the appointment of Richard Scheller, Ph.D., and Thomas Südhof, M.D., as co-chairs of the Company’s Strategic Portfolio Advice and...
Dec 13, 2019 06:28 am ET
Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D Day
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it will provide updates related to its lead product candidates during a previously announced R&D day being held today at 8:00...
Dec 11, 2019 04:05 pm ET
Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating Officer
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as the company’s president and chief operating officer. In this new role, Dr....
Dec 06, 2019 04:30 pm ET
Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported safety and biomarker data from the single ascending dose (SAD) phase of the INVOKE Phase1 study of its product candidate, AL002, in...
Dec 05, 2019 04:22 pm ET
Alector Announces FDA Fast Track Designation Granted to AL001 for the Treatment of Patients with Frontotemporal Dementia
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapeutic, AL001, for...
Dec 04, 2019 09:15 am ET
Alector to Host R&D Day on December 13, 2019
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it will host an R&D Day for analysts and investors on Friday, December 13, 2019 at 8:00 a.m. ET in New York City. The event...
Nov 14, 2019 08:30 am ET
Alector to Present at the Jefferies 2019 London Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer of Alector, will present at the Jefferies 2019 London Healthcare...
Nov 12, 2019 04:05 pm ET
Alector Reports Recent Business Highlights and Third Quarter 2019 Financial Results
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced Company highlights and financial results for the third quarter of 2019. “We continue to integrate insight from human genetics,...
Sep 09, 2019 08:00 am ET
Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001. AL001 is...
Sep 03, 2019 04:10 pm ET
Alector to Present at 17th Annual Morgan Stanley Global Healthcare Conference
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that Arnon Rosenthal, Ph.D., chief executive officer of Alector will participate in a fireside chat at the 17th Annual Morgan Stanley...
Aug 12, 2019 04:10 pm ET
Alector Reports Recent Business Highlights and Second Quarter 2019 Financial Results
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced company highlights and financial results for the second quarter of 2019. “We are continuing to make substantial progress in our...
Aug 12, 2019 09:00 am ET
Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors
Alector, Inc. (Nasdaq: ALEC) today announced the addition of Kristine Yaffe, M.D., to the Company’s board of directors. Dr. Yaffe is the Scola Endowed Chair and Vice Chair, professor of psychiatry, neurology and epidemiology and the director of the...
Jul 17, 2019 04:05 pm ET
Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported initial positive data from a subset of patients in the company’s INFRONT clinical study of its product candidate, AL001. AL001 is being...
Jul 11, 2019 06:30 am ET
Alector Announces Upcoming Presentations at 2019 Alzheimer's Association International Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced that the company will present clinical data from its AL001...
May 13, 2019 04:05 pm ET
Alector Reports Recent Business Highlights and First Quarter 2019 Financial Results
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced company highlights and financial results for the first quarter of...
May 08, 2019 04:05 pm ET
Alector to Present at the Bank of America Merrill Lynch Healthcare Conference on May 15, 2019
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced that members of the management team will present at the Bank of...
May 06, 2019 06:30 am ET
Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first Alzheimer’s disease patient in the Phase 1b...
Apr 17, 2019 04:05 pm ET
Alector Announces First Frontotemporal Dementia Patient Dosed in Phase 1b Study of AL001
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first frontotemporal dementia (FTD) patient in the...
Apr 01, 2019 04:30 pm ET
Alector Initiates Phase 1 Trial of AL003 for the Treatment of Patients with Alzheimer’s Disease
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of the first-in-human Phase 1 trial for AL003,...
Mar 26, 2019 04:15 pm ET
Alector Reports Recent Business Highlights and Fourth Quarter and Full Year 2018 Financial Results
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced company highlights and financial results for the fourth quarter...
Mar 06, 2019 05:15 pm ET
Alector to Present at Investor Conferences in March
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration today announced that members of the management team will present at the following...
Feb 07, 2019 03:18 pm ET
Nasdaq Welcomes Alector, Inc. (Nasdaq: ALEC) to the Nasdaq Stock Market
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company, rang the Nasdaq MarketSite bell in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. Alector is pioneering immuno-neurology, a...
Feb 06, 2019 07:59 pm ET
Alector Announces Pricing of Initial Public Offering
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the pricing of its initial public offering of 9,250,000 shares of common stock to the public at $19.00 per share. The gross proceeds to Alector from the offering are expected to be $176 million, before deducting the underwriting discounts and commissions and offering expenses. In addition, Alector has granted the underwriters a 30-day option to purchase up to

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.